Shares of CoLucid Pharmaceuticals Inc. (CLCD), which are up nearly 32% year-do-date, touched an all-time high of $11.00 on Friday in the run up to the release of phase III trial results of its lead product candidate Lasmiditan.
from RTT - Biotech http://ift.tt/2bPpdaw
via IFTTT
No comments:
Post a Comment